Abstract:Cellular senescence is a form of proliferative arrest triggered in response to a wide variety of stimuli and characterized by unique changes in cell morphology and function. Although unable to divide, senescent cells remain metabolically active and acquire the ability to produce and secrete bioactive molecules, some of which have recognized pro-inflammatory and/or pro-tumorigenic actions. As expected, this “senescence-associated secretory phenotype (SASP)” accounts for most of the non-cell-autonomous effects of senescent cells, which can be beneficial or detrimental for tissue homeostasis, depending on the context. It is now evident that many features linked to cellular senescence, including the SASP, reflect complex changes in the activities of mTOR and other metabolic pathways. Indeed, the available evidence indicates that mTOR-dependent signaling is required for the maintenance or implementation of different aspects of cellular senescence. Thus, depending on the cell type and biological context, inhibiting mTOR in cells undergoing senescence can reverse senescence, induce quiescence or cell death, or exacerbate some features of senescent cells while inhibiting others. Interestingly, autophagy—a highly regulated catabolic process—is also commonly upregulated in senescent cells. As mTOR activation leads to repression of autophagy in non-senescent cells (mTOR as an upstream regulator of autophagy), the upregulation of autophagy observed in senescent cells must take place in an mTOR-independent manner. Notably, there is evidence that autophagy provides free amino acids that feed the mTOR complex 1 (mTORC1), which in turn is required to initiate the synthesis of SASP components. Therefore, mTOR activation can follow the induction of autophagy in senescent cells (mTOR as a downstream effector of autophagy). These functional connections suggest the existence of autophagy regulatory pathways in senescent cells that differ from those activated in non-senescence contexts. We envision that untangling these functional connections will be key for the generation of combinatorial anti-cancer therapies involving pro-senescence drugs, mTOR inhibitors, and/or autophagy inhibitors.

MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation

mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype

Rapamycin and other longevity-promoting compounds enhance the generation of mouse induced pluripotent stem cells.

Persistent mTORC1 signaling in cell senescence results from defects in amino acid and growth factor sensing

Author Correction: MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation

Hypothalamic Mtorc2 is Essential for Metabolic Health and Longevity

Inhibition of S6K lowers age-related inflammation and increases lifespan through the endolysosomal system

Rapamycin fed late in life extends lifespan in genetically heterogeneous mice

A mild increase in nutrient signaling to mTORC1 in mice leads to parenchymal damage, myeloid inflammation and shortened lifespan

Rapalink-1 reveals novel mTOR-dependent genes and an agmatinergic axis-based metabolic feedback regulating mTOR activity and lifespan

The mTORC1-autophagy pathway is a target for senescent cell elimination

mTORC2: A neglected player in aging regulation

Targeting the biology of aging with mTOR inhibitors

ATF-4 and hydrogen sulfide signalling mediate longevity in response to inhibition of translation or mTORC1

Targeting mTOR for Anti-Aging and Anti-Cancer Therapy

Attenuation of TORC1 signaling delays replicative and oncogenic RAS-induced senescence.

The mTOR pathway is necessary for survival of mice with short telomeres

Mtorc1-Rps15 Axis Contributes to the Mechanisms Underlying Global Translation Reduction During Senescence of Mouse Embryonic Fibroblasts

With TOR, Less is More: A Key Role for the Conserved Nutrient-Sensing TOR Pathway in Aging

The mTOR–lysosome axis at the centre of ageing

mTOR Activity and Autophagy in Senescent Cells, a Complex Partnership